Onco-Innovations Secures Real-World Data Ahead of Clinical Trial Phase

Onco-Innovations subsidiary Inka Health gains access to OneMedNet's iRWD™ platform to refine the development of ONC010, identify patient populations, and bolster its AI platform ahead of Phase 1 trials.

Onco-Innovations is methodically advancing its preparations for an initial clinical study. A key component of this strategy involves its subsidiary, Inka Health, which has now gained access to the iRWD™ platform from OneMedNet. This system, built on Palantir Foundry technology, provides curated oncology real-world data from the United States.

Strategic Data Access Aims to De-Risk Development

The company’s immediate focus is a pilot program, initiated following a technical evaluation period. This collaboration is centered on refining the development pathway for ONC010, a PNKP inhibitor designed to target tumors exhibiting PTEN/SHP1 deficiency. This rare molecular subgroup can be precisely characterized using the platform's AI-powered search capabilities.

Management intends to leverage this real-world data to identify potential patient populations, explore new indications beyond metastatic colorectal cancer, and bolster the regulatory evidence base before entering formal clinical trials. Chief Executive Thomas O'Shaughnessy emphasized that the partnership is designed to mitigate development risks and enhance capital efficiency for shareholders.

Broader Expansion and Platform Synergies

The move is part of a wider U.S. expansion strategy for Onco-Innovations. Beyond the planned commencement of Phase 1 trials in 2026, leadership is pursuing a cross-listing on a U.S. stock exchange.

Concurrently, the data access is expected to directly benefit Inka Health's proprietary AI platform, SynoGraph. Longitudinal, multimodal datasets will be used to refine the platform's causal inference model, aiming to improve the precision of its predictions for treatment outcomes and safety signals.

Upcoming Quarterly Report in Focus

Investors will get their next detailed look at the company’s progress on April 6, when Onco-Innovations releases its financial results for the third quarter of 2026. Market participants are likely to scrutinize the firm's capital position closely. This follows a non-brokered private placement in March that raised approximately CAD 1.2 million.

The stock currently trades roughly 56 percent below its 200-day moving average, a technical position that underscores the market's demand for a convincing quarterly report.